Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium.

Felix AS, Cook LS, Gaudet MM, Rohan TE, Schouten LJ, Setiawan VW, Wise LA, Anderson KE, Bernstein L, De Vivo I, Friedenreich CM, Gapstur SM, Goldbohm RA, Henderson B, Horn-Ross PL, Kolonel L, Lacey JV, Liang X, Lissowska J, Magliocco A, McCullough ML, Miller AB, Olson SH, Palmer JR, Park Y, Patel AV, Prescott J, Rastogi R, Robien K, Rosenberg L, Schairer C, Ou Shu X, van den Brandt PA, Virkus RA, Wentzensen N, Xiang YB, Xu WH, Yang HP, Brinton LA.

Br J Cancer. 2013 Feb 19;108(3):727-34. doi: 10.1038/bjc.2013.2. Epub 2013 Jan 24.

2.

Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors.

Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Brinton LA.

Gynecol Oncol. 1998 Jun;69(3):253-7.

PMID:
9648597
3.

Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus.

Schwartz SM, Weiss NS, Daling JR, Gammon MD, Liff JM, Watt J, Lynch CF, Newcomb PA, Armstrong BK, Thompson WD.

Cancer. 1996 Feb 15;77(4):717-24.

4.

A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.

Bland AE, Stone R, Heuser C, Shu J, Jazaeri A, Shutter J, Atkins K, Rice L.

Int J Gynecol Cancer. 2009 Feb;19(2):261-5. doi: 10.1111/IGC.0b013e31819a1fa5.

PMID:
19396006
5.

Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.

Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR.

Gynecol Oncol. 2006 Nov;103(2):684-7. Epub 2006 Jun 23.

PMID:
16797683
6.

The epidemiology of sarcomas of the uterus.

Harlow BL, Weiss NS, Lofton S.

J Natl Cancer Inst. 1986 Mar;76(3):399-402.

PMID:
3456457
7.

Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium.

Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, Adami HO, Beresford S, Bernstein L, Chen C, Cook LS, De Vivo I, Doherty JA, Friedenreich CM, Gapstur SM, Hill D, Horn-Ross PL, Lacey JV, Levi F, Liang X, Lu L, Magliocco A, McCann SE, Negri E, Olson SH, Palmer JR, Patel AV, Petruzella S, Prescott J, Risch HA, Rosenberg L, Sherman ME, Spurdle AB, Webb PM, Wise LA, Xiang YB, Xu W, Yang HP, Yu H, Zeleniuch-Jacquotte A, Brinton LA.

Int J Cancer. 2015 Mar 1;136(5):E410-22. doi: 10.1002/ijc.29229. Epub 2014 Sep 30.

8.

Incidence of histologic types of uterine sarcoma in relation to menstrual and reproductive history.

Schwartz SM, Weiss NS, Daling JR, Newcomb PA, Liff JM, Gammon MD, Thompson WD, Watt JD, Armstrong BK, Weyer P, et al.

Int J Cancer. 1991 Sep 30;49(3):362-7.

PMID:
1917134
9.

Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients.

Arem H, Park Y, Pelser C, Ballard-Barbash R, Irwin ML, Hollenbeck A, Gierach GL, Brinton LA, Pfeiffer RM, Matthews CE.

J Natl Cancer Inst. 2013 Mar 6;105(5):342-9. doi: 10.1093/jnci/djs530. Epub 2013 Jan 7.

10.

Marital status and the incidence of sarcomas of the uterus.

Schwartz SM, Weiss NS.

Cancer Res. 1990 Mar 15;50(6):1886-9.

11.

The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.

Tong SY, Lee JM, Choi YJ, Lee JK, Kim JW, Cho CH, Kim SM, Park SY, Park CY, Kim KT.

Aust N Z J Obstet Gynaecol. 2012 Feb;52(1):44-8. doi: 10.1111/j.1479-828X.2011.01389.x. Epub 2011 Dec 20.

PMID:
22188343
13.

Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.

Burghaus S, Halmen S, Gass P, Mehlhorn G, Schrauder MG, Lux MP, Renner SP, Beckmann MW, Hein A, Thiel FC.

Arch Gynecol Obstet. 2016 Aug;294(2):343-51. doi: 10.1007/s00404-015-3993-6. Epub 2015 Dec 28.

PMID:
26711836
14.

Does fertility treatment increase the risk of uterine cancer? A meta-analysis.

Saso S, Louis LS, Doctor F, Hamed AH, Chatterjee J, Yazbek J, Bora S, Abdalla H, Ghaem-Maghami S, Thum MY.

Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:52-60. doi: 10.1016/j.ejogrb.2015.09.002. Epub 2015 Oct 3. Review.

PMID:
26476799
15.

Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.

Mikami Y, Hata S, Kiyokawa T, Manabe T.

Mod Pathol. 2002 Sep;15(9):923-30.

16.

The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women.

Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, Plaxe SC.

Am J Obstet Gynecol. 2013 Dec;209(6):579.e1-5. doi: 10.1016/j.ajog.2013.08.007. Epub 2013 Aug 11.

PMID:
23938608
17.

Modelling body mass index and endometrial cancer risk in a pooled-analysis of three case-control studies.

Rota M, Rumi F, Bagnardi V, Dal Maso L, Zucchetto A, Levi F, La Vecchia C, Tavani A.

BJOG. 2016 Jan;123(2):285-92. doi: 10.1111/1471-0528.13717. Epub 2015 Nov 6.

18.

Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.

Pautier P, Genestie C, Rey A, Morice P, Roche B, Lhommé C, Haie-Meder C, Duvillard P.

Cancer. 2000 Mar 15;88(6):1425-31.

PMID:
10717626
19.

Hormone-related factors and gynecological conditions in relation to endometrial cancer risk.

Zucchetto A, Serraino D, Polesel J, Negri E, De Paoli A, Dal Maso L, Montella M, La Vecchia C, Franceschi S, Talamini R.

Eur J Cancer Prev. 2009 Aug;18(4):316-21.

PMID:
19554665
20.

Second primary malignancies among women with uterine sarcoma.

Koivisto-Korander R, Scélo G, Ferro G, Mellemkjaer L, Hemminki K, Weiderpass E, Tamaro S, Pompe-Kirn V, Tracey E, Brewster DH, Kliewer EV, Tonita JM, Kee-Seng C, Jonasson JG, Martos C, Brennan P, Straif K, Pukkala E.

Gynecol Oncol. 2012 Jul;126(1):30-5. doi: 10.1016/j.ygyno.2012.04.002. Epub 2012 Apr 6.

PMID:
22487538

Supplemental Content

Support Center